Language: Spanish
References: 78
Page: 1-34
PDF size: 259.09 Kb.

Text Extraction

No abstract.

REFERENCES

1. Minsap. Anuario estadístico [homepage en Internet]; La Habana, 2011 [citado 13 de febrero de 2013]. Disponible en: http://files.sld.cu/dne/files/2012/04/anuario- 2011-e.pdf

2. NIH. Consensus Development Panel on Osteoporosis: prevention, diagnostic and therapy. JAMA. 2001:285;785-95.

3. Alfonso Fraga JC. Cuba, características sociodemográficas de las mujeres de edad mediana. En: Artiles L, Navarro D, Manzano BR, eds. Climaterio y menopausia, un enfoque desde lo social. La Habana: Editorial Científico Técnica; 2007. p. 21-37.

4. Lorenzo JA, Canals E, Raisz L. Enfermedad metabólica ósea. En: Kronenberg HM, Melmed S, Polonsjy K, Red Larsen P, eds. Tratado de Endocrinología. 11na edición. Capítulo 28. Madrid: Elsevier; 2010. p. 1373-402.

5. Supervia Caparráas A, Diez Pérez A. Epidemiología de la osteoporosis y de las fracturas. Actualizaciones en Osteoporosis. Madrid: Ergon; 2006. p. 19-34.

6. Navarro Despaigne D. Estrógenos y huesos. En: Artiles L, Navarro D, Manzano BR, eds. Climaterio y menopausia, un enfoque desde lo social. La Habana: Editorial Científico Técnica; 2007. p. 202-15.

7. Díaz López JB, Gómez Alonso C. Concepto de osteoporosis: masa ósea vs. calidad ósea. Actualizaciones en Osteoporosis. Madrid: Ergon; 2006. p. 3-18.

8. Olmos Martínez JM, González Macías J. Nuevos aspectos del remodelado óseo. Actualizaciones en Osteoporosis. Madrid: Ergon; 2006. p. 35-54.

9. Actualización 2011 del Consenso Sociedad Española de Reumatología de Osteoporosis. Reumatol Clin. 2011;7:357-79.

10. Guías 2012 para el diagnóstico, la prevención y el tratamiento de la osteoporosis. Medicina (Buenos Aires). 2013;73:55-74.

11. Sen SS, Rives VP, Messina OD, Morales-Torres J, Riera G, Angulo-Solimano JM, Neto JF, et al. A risk assessment tool (OsteoRisk) for identifying Latin American women with osteoporosis. J Gen Intern Med. 2005;20:245-50.

12. Von Mühlen D, Visby Lunde A, Barrett-Connor E, Bettencourt R. Evaluation of the simple calculated osteoporosis risk estimation (SCORE) in older Caucasian women: the Rancho Bernardo study. Osteoporos Int. 1999;10:79-84.

13. Hiligsmann M, Ethgen O, Richy F, Reginster JY. Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcif Tissue Int. 2008;82:288-92.

14. Rud B, Jensen JE, Mosekilde L, Nielsen SP, Hilden J, Abrahamsen B. Performance of four clinical screening tools to select peri-and early postmenopausal women for dual X-ray absorptiometry. Osteoporos Int. 2005;16:764-72.

15. Gourlay ML, Miller WC, Richy F, Garrett JM, Hanson LC, Reginster JY. Performance of osteoporosis risk assessment tools in postmenopausal women aged 45-64 years. Osteoporos Int. 2005;16:921-7.

16. Salaffi F, Silveri F, Stancati A, Grassi W. Development and validation of the osteoporosis prescreening risk assessment (OPERA) tool to facilitate identification of women likely to have low bone density. Clin Rheumatol. 2005;24:203-11.

17. Koh LK, Sedrine WB, Torralba TP, Kung A, Fujiwara S, Chan SP, et al . A simple tool to identify asian women at increased risk of osteoporosis. Osteoporosis Self-Assessment tool for Asians (OSTA) Research Group. Osteoporos Int. 2001;12:699-705.

18. Farrerons Minguella J, Malouf J. Radiología de la fractura vertebral. Actualización en Osteoporosis. Madrid: Ergon; 2006. p. 29-43.

19. Marshall D, Johnell 0, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254-9.

20. Bosnick SL. Densitometry techniques. In: Bone densitometry in clinical practice. Second Edition. Chapter 1. New Jersey: Humana Press; 2004. p. 1-22.

21. Green AD, Colón-Emeric CS, Bastian L, Drake MT, Lyles KW. Does this woman have osteoporosis? JAMA. 2004;292:2890-900.

22. Bosnick SL. Diadnosing osteoporosis. In: Bone densitometry in clinical practice. Second Edition. Chapter 9. New Jersey: Humana Press; 2004. p. 197-215.

23. Santos C. Criterios Normativos de Diagnóstico de la Osteoporosis y la Composición Corporal en Población Cubana según Densitometría de Doble Haz de Fotones [monografía en Internet] [citado 26 de agosto de 2013]. Disponible en: http://www.monografias.com/trabajos16/criterios osteoporosis/criterios osteoporosis.html.

24. Santos C, Navarro D, Manzano B. Riesgo relativo de osteoporosis según la densidad mineral ósea en mujeres menopáusicas sanas de la región occidental de Cuba. Rev Esp Nutr Comunitaria. 2010;16:137-46.

25. Granela Cortiñas K, Pérez Gesen C, Carvajal Martínez F, Navarro Despaigne D, Domínguez Alonso E, Díaz Horta O, et al. Mineralización ósea en niños y adolescentes con hipotiroidismo congénito. Rev Cubana Endocrinol. 2011 Ago;22:118-32.

26. Díaz Curiel M. Epidemiología, fisiopatología y diagnóstico de la osteoporosis del varón. En: Actualizaciones en Osteoporosis masculina. Madrid: Ergon; 2011. p. 7-22.

27. Sosa Henríquez M, Gómez de Tejada Romero MJ. Densitometría vs. ultrasonidos en el diagnóstico de la osteoporosis. En: Actualizaciones en Osteoporosis. Madrid: Ergon; 2006. p. 1-17.

28. Santisteban Alba S. Climaterio y osteoporosis. En: Artiles L, Navarro D, Manzano BR, eds. Climaterio y Menopausia, un enfoque desde lo social. La Habana: Editorial Científico Técnica; 2007. p. 313-26.

29. Arrebola A. Prevención general de la osteoporosis: papel de la dieta y del ejercicio. Actualización en osteoporosis. Madrid: Ergon; 2006. p. 43-66.

30. Dirección General de Farmacia y Productos Sanitarios de Madrid. Recomendaciones para la valoración y tratamiento de la osteoporosis primaria en mujeres de la Comunidad de Madrid. Comunidad de Madrid: Conserjería de Sanidad; 2007.

31. Watts NB, Lewiecki EM, Miller PD, Baim S. National Osteoporosis Foundation Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist. J Clin Densitom. 2008;11:473-7.

32. Consenso 2010 de la Sociedad Norteamericana de Menopausia. Manejo de la osteoporosis en mujeres posmenopáusicas. Revista de Climaterio. 2012;13:139-88.

33. 2012 update of French guidelines for the pharmacological treatment of postmenopausal Osteoporosis. Joint Bone Spine. 2012;79:304-13.

34. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson- Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005;11(293):2257-64.

35. Bischoff-Ferrari HA. Which vitamin D oral supplement is best for postmenopausal women? Curr Osteoporos Rep. 2012;10:251-7.

36. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911-30.

37. Body J, Bergmann P, Boonen S, Boutsen Y, Bruyere O, Devogelaer JP, et al. Nonpharmacological management of osteoporosis:a consensus of the Belgian Bone Club. Osteoporos Int. 2011;22:2769-88.

38. Hongo M, Itoi E, Sinaki M, Miyakoshi N, Shimada Y, Maekawa S, et al. Effect of lowintensity back exercise on quality of life and back extensor strength in patients with osteoporosis: a randomized controlled trial. Osteoporos Int. 2007;18(1):389-1395.

39. Pérez Edo I. Bisfosfonatos. Actualizaciones en Osteoporosis. Madrid: Ergon; 2007. p. 61-8.

40. Gómez de Tejada Romero MJ, Pérez Cano R. Fármacos antirresortivos II: el tratamiento hormonal sustitutivo, los moduladores selectivos de los receptores estrogénicos y la calcitonina. Actualizaciones en Osteoporosis. Madrid: Ergon; 2007. p. 23-42.

41. Kumar Khajuria D, Razdan R, Mahapatra DR. Drugs for the management of osteoporosis: a review Rev Bras Reumatol. 2011;51:365-82.

42. Pazianas M, Cooper C, Ebetino H, Graham R, Russell G. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Therapeutics and Clinical Risk Management. 2010;6:325-43.

43. Salica D, Buceta A, Palacios S, Sánchez A, y grupo investigadores SIBOMM. Consenso Iberoamericano de Osteoporosis SIBOMM 2009. Osteoporosis: Prevención, Diagnóstico y Tratamiento. Rev Arg Osteol. 2010;9:4-44.

44. Jervis R. Osteopenia-osteoporosis. Rev Ecuatoriana de Ginecología y Obstetricia. 2011;XVIII:97-103.

45. Claus-Hermberg H, Bagur A, Messina O, Negri A, Schurman L, Sánchez A. FRAX. Un nuevo instrumento para calcular el riesgo absoluto de fractura a 10 años. Medicina (B Aires). 2009;69:571-5.

46. Fraser LA, Vogt K, Adachi J, Thabane L. Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis. Therapeutics and Clinical Risk Management. 2011;7:157-66.

47. Watts NB, Diab D. Long term use of bisphosphonates in Osteoporosis. J Clin Endocrinol Metab. 10;95:1555-65.

48. Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, et al. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab. 2012;97:2272-82.

49. Orwoll E, Teglbjærg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL, et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab. 2012;97:3161-9.

50. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Welch V, et al. Risedronate forthe primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews. 2008; Issue 1. Art. No. CD004523.

51. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637-45.

52. Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown, JP Czerwin E, et al. Five years of Denosumab exposure in women with postmenopausal Osteoporosis: Results From the First Two Years of the FREEDOM Extension. JBMR. 2012;27:694-705.

53. Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000;109:267-76.

54. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. Osteoporos Int. 2005;16:372-9.

55. Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 2013;6(382):50-6.

56. Finkelstein JS, Wyland JJ, Lee H, Neer RM. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2010;95:1838-45.

57. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005;90:2816-22.

58. Writing Group for the Women's Health Initiative. JAMA. 2002;288:321-33.

59. Egerdie RB, Saad F, Smith MR, Tammela TL, Heracek J, Sieber P, et al. Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2012;15:308-12.

60. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;4:23-57.

61. Silverman SL, Cummings SR, Watts NB; Consensus Panel of the ASBMR, ISCD, and NOF. Recommendations for the clinical evaluation of agents for treatment of Osteoporosis Consensus of an expert panel representing the American Society for Bone and Mineral Research (ASBMR), the International Society for Clinical Densitometry (ISCD), and the National Osteoporosis Foundation (NOF). J Bone Miner Res. 2008;23:159-65.

62. Kanis JA, Gluer CC. An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int. 2000;11:192-202.

63. World Health Organization. Prevention and management of osteoporosis. World Health Organ Tech Rep Ser. 2003;921:1-164.

64. Bosnick SL. Reporting densitometry. In: Bone densitometry in clinical practice. Second Edition. Chapter 12. New Jersey: Humana Press; 2004. p. 267-85.

65. Richy F, Lecart MP, Mawet AM, Paquot B, Reginster JY. Value of bone densitometry for the diagnosis and monitoring of osteoporotic patients: integration with biological and clinical risk factors. Rev Med Liege. 2006 May-Jun;61(5-6):291-300.

66. Goldbloom EB, Cummings EA, Yhap M. Osteoporosis at presentation of childhood all: Management with Pamidronate. Pediatric Hematology and Oncology. 2005;22:543-50.

67. Sebestyen JF, Srivastava T, Alon US. Bisphosphonates use in children. Clin Pediatr Phila. 2012;51:1011-24.

68. Giampiero I, Baroncell B, Bertelloni S, Sodin F, Saggese G. Osteoporosis in children and adolescents. Aetiology and management Review. Pediatr Drugs. 2005;7:295-323.

69. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004;48:271-87.

70. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004;15:1003-8.

71. Van der Velde N, Stricker BH, Pols HA, Van der Cammen TJ. Risk of falls after withdrawal of fall-risk-increasing drugs: a prospective cohort study. Br J Clin Pharmacol. 2007;63:232-7.

72. Szulc P, Muños P, Duboeuf F, Marchand F, Delmas PB. Bone mineral density predicts osteoporotic fractures in elderly men. The MINOS study. Osteoporos Int. 2005;16:1184-92.

73. McLeod KM, Johnson CS. Identifying women with low bone mass: a systematic review of screening tools. Geriatr Nurs. 2009;30:164-73.

74. Liu J, Ho SC, Su YX, Chen WQ, Zhang CX, Chen YM. Effect of long-term intervention of soy isoflavones on bone mineral density in women: a meta-analysis of randomized controlled trials. Bone. 2009;44:948-53.

75. Martínez A. Terapia de reemplazo o fitoestrógenos. Rev Ecuatoriana de Ginecología y Obstetricia. 2011;XVIII:94-7.

76. Marini H, Minutoli L, Polito F, Bitto A, Altavilla D, Atteritano M. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women a randomized controlled trial. Ann Intern Med. 2007;19(146):839-47.

77. Montero M, Diaz M, Guede D, Caeiro JR, Martinez M, Navarro D, et al. Effects of Kalsis, A Dietary Supplement, on Bone Metabolism in the Ovariectomized Rats. J of Osteoporosis. 2012;Article ID 639427.

78. Navarro D, Triana M. Efectos del kalsis como coadyuvante en el tratamiento de la baja masa ósea (osteopenia) en mujeres de edad mediana. Rev Colombiana de Menopausia. 2010;16:307-18.